Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Posted by Geri Gentry on May 12th, 2026

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) had its target price lifted by equities research analysts at Needham & Company LLC from $18.00 to $41.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 286.79% from the company’s current price.

Several other research firms have also recently weighed in on ARTV. Wedbush boosted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday. Cantor Fitzgerald boosted their price objective on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. HC Wainwright boosted their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Artiva Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $39.00.

Check Out Our Latest Analysis on ARTV

Artiva Biotherapeutics Stock Performance

ARTV opened at $10.60 on Tuesday. The company has a market cap of $262.03 million, a PE ratio of -2.99 and a beta of 2.86. The stock has a 50-day moving average of $7.81 and a 200-day moving average of $5.43. Artiva Biotherapeutics has a 52-week low of $1.47 and a 52-week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, research analysts predict that Artiva Biotherapeutics will post -3.33 earnings per share for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new position in Artiva Biotherapeutics in the 1st quarter valued at approximately $131,000. Sanctuary Advisors LLC acquired a new position in Artiva Biotherapeutics in the 1st quarter valued at approximately $139,000. Simplify Asset Management Inc. acquired a new position in Artiva Biotherapeutics in the 1st quarter valued at approximately $150,000. OMERS ADMINISTRATION Corp acquired a new position in Artiva Biotherapeutics in the 4th quarter valued at approximately $91,000. Finally, Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the 4th quarter valued at approximately $341,000.

Trending Headlines about Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

Positive Sentiment: Cantor Fitzgerald lifted its price target on Artiva Biotherapeutics to $40 and kept an overweight rating, signaling strong upside potential. Cantor Fitzgerald Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price
Positive Sentiment: Wedbush also raised its target to $40 and maintained an outperform rating, reinforcing bullish sentiment around the stock. Wedbush Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price
Neutral Sentiment: HC Wainwright increased FY2026, Q2 2026, Q3 2026, Q4 2026, and FY2030 EPS estimates, suggesting improving earnings visibility. HC Wainwright estimate updates for Artiva Biotherapeutics
Negative Sentiment: HC Wainwright lowered FY2027, FY2028, and FY2029 EPS estimates, which tempers the longer-term optimism. HC Wainwright estimate revisions for Artiva Biotherapeutics

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.